Pila Pharma AB (publ)

Stockholm Stock Exchange PILA.ST

Pila Pharma AB (publ) Free Cash Flow Yield on January 14, 2025: -4.47%

Pila Pharma AB (publ) Free Cash Flow Yield is -4.47% on January 14, 2025, a 67.30% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Pila Pharma AB (publ) 52-week high Free Cash Flow Yield is -2.48% on July 12, 2024, which is 44.64% above the current Free Cash Flow Yield.
Pila Pharma AB (publ) 52-week low Free Cash Flow Yield is -18.42% on March 25, 2024, which is -311.78% below the current Free Cash Flow Yield.
Pila Pharma AB (publ) average Free Cash Flow Yield for the last 52 weeks is -7.46%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: PILA.ST

Pila Pharma AB (publ)

CEO	Mr. Gustav Hanghoj Gram
IPO Date	July 15, 2021
Location	Sweden
Headquarters	VAestergatan 1
Employees	1
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.

Key trends

Past 5 years